Firms handling GLP-1 injury claims win AI citations in 2026 by publishing the procedural posture of MDL 3094, not by publishing intake copy. MDL 3094 sits in the Eastern District of Pennsylvania and consolidates claims that GLP-1 receptor agonists including Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, and Trulicity caused gastroparesis, intestinal obstruction, and related gastrointestinal injuries. Case counts reported through 2026 ranged from roughly 3,848 pending in July filings to 4,700-plus earlier in the year, with Case Management Order No. 30 from January 2026 pushing the docket toward expert disclosures and a Rule 702 hearing set for September 2026 before any bellwether trial. Firms that publish those facts with dates get quoted by ChatGPT, Perplexity, and Google AI Overviews. Firms that publish “you may qualify for compensation” do not get quoted at all.
GLP-1 is the most competitive mass tort advertising category in the country right now, which means the paid channel is expensive and crowded. The AI answer layer is neither, yet. That asymmetry is the entire opportunity.
Which GLP-1 lawsuit queries are people actually asking AI engines?
The query set splits into five recognizable shapes, and only two of them are being answered well by anyone.
Drug specific eligibility leads: “can I sue for Ozempic gastroparesis,” “is there a Mounjaro lawsuit,” “does Wegovy cause stomach paralysis.” Injury specific queries follow: “what is gastroparesis from Ozempic,” “Ozempic NAION vision loss lawsuit,” “GLP-1 bowel obstruction claim.” Status queries are third: “what is the status of MDL 3094,” “when is the Ozempic bellwether trial,” “has Ozempic settled.” Timeline queries are fourth: “how long do I have to file an Ozempic lawsuit.” And comparison queries, the newest group, ask which drugs are covered: “is Zepbound part of the Ozempic lawsuit.”
Status and comparison are the underserved pair. Nearly every firm page covers eligibility. Almost none maintains an accurate current list of which manufacturers and which brand names are in scope, or where the docket actually stands this month. Those are the passages engines need and cannot find.
Buying GLP-1 intake and want to know if AI engines ever name your firm? Get a free AI visibility audit and see the specific prompts where your competitors show up.
What content structure earns citations on pharma litigation?
Five page types, each on its own URL. AI retrieval operates on passages within pages, so a single 6,000 word mega page competes with itself. Split it.
1. Docket status page, updated monthly
Names MDL 3094, the Eastern District of Pennsylvania, the defendants Novo Nordisk and Eli Lilly, the current pending case count with the date it was measured, the CMO governing the current phase, and the next scheduled milestone. The September 2026 Rule 702 hearing is exactly the kind of dated, checkable fact engines quote. Put the update date in visible body text.
2. Drug and manufacturer scope page
A table listing every brand name in the litigation against its manufacturer and active ingredient: Ozempic, Wegovy, and Rybelsus (semaglutide, Novo Nordisk); Saxenda and Victoza (liraglutide, Novo Nordisk); Mounjaro and Zepbound (tirzepatide, Eli Lilly); Trulicity (dulaglutide, Eli Lilly). This single table answers a dozen distinct queries and is the most quotable asset a GLP-1 firm can publish. Tables outperform prose in retrieval, as we covered in table formatting for AI citations.
3. Injury definition pages
Separate pages for gastroparesis, ileus and intestinal obstruction, and NAION vision loss. Each explains the condition in plain language, cites medical literature, and states what documentation a claim typically requires. These pages capture the enormous informational query volume around “what is gastroparesis” and establish topical depth that makes the litigation pages retrievable.
4. Eligibility criteria page, with exclusions
Publish the disqualifiers, not just the qualifiers. Prior diabetic gastroparesis diagnosis, insufficient duration of use, missing prescription records: naming what does not qualify is rare on the open web, so it gets cited, and it cuts unqualified intake volume at the same time.
5. State filing and limitations page
Statutes of limitation for product liability run two to four years in most states, with discovery rule variations that matter enormously here because gastroparesis is frequently misdiagnosed for months. One page per state where the firm files, each naming the state, the limitations period, and the discovery rule treatment.
Which schema markup and technical signals matter?
LegalService and Attorney schema for the firm entity, FAQPage schema on eligibility and status pages, and Article schema with accurate datePublished and dateModified on every page that carries litigation facts. The dateModified field is not cosmetic on a docket page: freshness is a measured retrieval input, and 2026 analyses have found pages updated within roughly two months earn meaningfully higher citation rates than older ones.
Use about and mentions entity properties aggressively. Name semaglutide, tirzepatide, Novo Nordisk, Eli Lilly, gastroparesis, MDL 3094, and the Eastern District of Pennsylvania explicitly in markup. Entity association is how a retrieval system connects “stomach paralysis lawsuit” to a page that never uses that exact phrase. Our legal schema markup guide has the full patterns.
Two technical items get missed constantly. First, confirm your robots.txt does not block GPTBot, PerplexityBot, ClaudeBot, OAI-SearchBot, or Google-Extended, since blocking them removes you from the index that produces citations. Second, make sure litigation content renders in server side HTML rather than client side JavaScript, because several AI crawlers do not execute JS reliably. Both are covered in can ChatGPT see my website.
How do GLP-1 firms build authority off their own domain?
Third party presence drives citations far more than owned content. Current measurement puts brands roughly 6.5x more likely to be cited through third party sources than through their own domains, and in legal queries that skew is stronger because engines lean on directories and trade press for attorney credentialing.
Four surfaces matter. Legal directories first: Avvo, Martindale-Hubbell, Justia, Super Lawyers, and Lawyers.com, with practice area fields set to product liability and mass tort rather than generic personal injury. Legal trade press second: Law360, Reuters Legal, Bloomberg Law, and Law.com cover MDL 3094 case management developments and quote plaintiff and defense counsel by name. Medical and consumer health press third, because GLP-1 injury coverage runs in outlets like STAT News, Reuters Health, and consumer titles that legal marketers usually ignore, and those outlets get retrieved heavily on injury queries. Fourth, MDL tracking publishers and drug injury news sites, which currently dominate status query results; being quoted there beats trying to outrank them.
The highest return move is original data. Nobody has published a state by state analysis of GLP-1 gastroparesis filings, or a breakdown of average time from first prescription to diagnosis across a claim population. A firm sitting on hundreds of intakes has that data. Publishing an anonymized, methodologically clean version of it creates a source with no competitor, which is the mechanism described in original research for AI citations.
What are the compliance and accuracy risks specific to GLP-1 content?
Three risks, and the first one is unique to this litigation. GLP-1 drugs are widely prescribed and clinically effective for their approved uses. Content that reads as a blanket warning against taking them creates a medical misinformation problem, and 2026 quality signals penalize health adjacent pages that overstate risk. State the litigation allegations as allegations, cite the FDA label changes that actually occurred, and do not advise anyone to stop a prescription.
Second, case value claims. Settlement speculation is everywhere in this category because no bellwether has tried. Publishing projected settlement ranges before a single verdict exists is both unsupportable and, in most states, a bar advertising problem. Firms are better served publishing what determines value in product liability generally: injury severity, medical expense documentation, duration of use, and causation evidence quality.
Third, scope accuracy. The list of covered drugs and defendants has shifted as the MDL has developed, and stale pages naming the wrong scope get corrected by engines against fresher sources, which suppresses future citation of that domain. A quarterly accuracy review of every GLP-1 page is not optional maintenance, it is the core of the program.
How do you measure GLP-1 AEO performance?
Rank tracking will not capture it. Track four signals monthly.
Run a fixed prompt set of 30 to 50 GLP-1 queries through ChatGPT, Perplexity, Google AI Mode, and Copilot on a schedule and record firm mentions. Tools including Profound, Otterly, Peec AI, and Semrush’s AI toolkit automate this; a spreadsheet works at this volume. Track branded search impressions in Google Search Console, which move before referral traffic does. Segment referral traffic from chatgpt.com, perplexity.ai, and copilot.microsoft.com as a distinct analytics channel; AI referrals sit near 1 percent of total web traffic industry wide but convert at multiples of standard organic for service businesses. And log verbatim “how did you hear about us” answers on every intake call, which remains the highest signal data source available.
Expect 60 to 90 days for structural changes to affect citation frequency on an established domain, and two quarters for third party authority work. Anyone promising faster is describing paid placement, not AEO. The broader mass tort framework is in AEO for mass tort firms.
Frequently asked questions
What is MDL 3094 and where does it stand? MDL 3094 is In re: Glucagon-Like Peptide-1 Receptor Agonists Products Liability Litigation, pending in the U.S. District Court for the Eastern District of Pennsylvania. It consolidates claims that GLP-1 drugs from Novo Nordisk and Eli Lilly caused gastroparesis and other gastrointestinal injuries. Reported pending case counts in 2026 ranged from roughly 3,848 in July filings to over 4,700 earlier in the year. A Rule 702 expert admissibility hearing was scheduled for September 2026, a threshold that must clear before bellwether trials proceed.
Which drugs are included in the GLP-1 litigation? The litigation covers semaglutide products Ozempic, Wegovy, and Rybelsus and liraglutide products Saxenda and Victoza, all from Novo Nordisk, alongside tirzepatide products Mounjaro and Zepbound and dulaglutide product Trulicity from Eli Lilly. Scope has shifted as the MDL developed, so firms should verify the current inclusion list against the operative case management orders before publishing. Publishing an outdated scope list is a common accuracy failure that suppresses future citations.
Why do AI engines cite drug injury news sites instead of law firms? Because those sites publish dated procedural updates with named entities and law firms publish static conversion pages. A retrieval system looking for the current status of MDL 3094 needs a passage containing the docket number, the court, a case count, and a date. Aggregators produce that monthly. Most firm pages produce eligibility language written a year ago. The remedy is a maintained status page, not more pages.
Should a firm publish estimated GLP-1 settlement amounts? No. No bellwether has been tried and no global settlement exists, so any published range is speculation. Beyond the accuracy problem, most state bar advertising rules restrict case value representations and require disclaimers about prior results. Publishing the factors that determine product liability value, meaning injury severity, documented medical expenses, duration of use, and causation evidence, answers the underlying question honestly and is far more likely to be cited.
How much does GLP-1 AEO cost compared to paid intake? GLP-1 is among the most expensive paid legal categories, with competitive cost per qualified lead frequently running into the high hundreds or low thousands of dollars depending on market and channel. AEO work is a fixed content and technical investment rather than a per lead cost, so the economics invert over time: paid cost scales linearly with volume while citation authority compounds. The honest tradeoff is speed, since paid produces leads this week and AEO produces them in a quarter.
Does blocking AI crawlers protect a firm’s content? It removes the firm from the answers. Blocking GPTBot, PerplexityBot, ClaudeBot, or Google-Extended in robots.txt prevents those systems from retrieving your pages, which means they cite someone else on every query in your practice area. Some publishers block crawlers to protect subscription revenue, which is a different business model. For a law firm whose content exists to generate intake, blocking retrieval bots removes the only mechanism by which the content produces clients.
The takeaway
GLP-1 is the rare mass tort where the paid channel is saturated and the answer channel is wide open. Every firm in the category is bidding against every other firm for the same clicks, while the question “what is the status of the Ozempic lawsuit” gets answered daily by engines pulling from news aggregators because no law firm bothered to maintain a current, factual, entity dense page. Building that page and its four companions is a week of work and a quarterly maintenance habit. The firms that treat it as a publishing obligation rather than a marketing campaign will be the ones AI engines name when the bellwethers finally reach a jury.
Want to see whether your firm appears on Ozempic and Mounjaro prompts right now? Run the free AI visibility audit and get the query level results before your next media buy.
Tagged